Finding the Line Separating Infringement and Exempt Uses: Enforcing Biotechnology Patents in View of 35 U.S.C. § 271(e)(1)
Biotechnology patented research method or tool and role of FDA data submission requirement in 35 U.S.C. § 271(e)(1) infringement safe harbor.
For nearly a decade, companies involved in basic biotechnology research could rely on guidance from the Supreme Court in Merck KGaA v. Integra Lifesciences,1 which considered the scope of the 35 U.S.C. § 271(e)(1) statutory safe harbor. The statute states that:
1. Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005).
2. 35 U.S.C. § 271(e)(1).
Reproduced with permission from Life Sciences Law & Industry Report, 8 LSLR 321, 04/04/2014. Copyright 2014 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.